Linked research, clinical, and regulatory source pathways.
Company profile
About Cancer Genetics
SOPHiA GENETICS is a health technology company that has built SOPHiA DDM™, an AI-driven platform for precision medicine that analyzes complex health data to provide actionable clinical insights. The platform serves healthcare providers, biopharma companies, and patients globally, focusing primarily on oncology and rare genetic disorders. SOPHiA DDM™ processes genomic, radiomic, and multimodal data through advanced AI algorithms that achieve 98-99% accuracy across multiple applications. The company's technology supports end-to-end workflows for solid tumors, blood cancers, hereditary cancers, liquid biopsy, and inherited disorders. With a network of over 990 healthcare institutions across 75+ countries, SOPHiA GENETICS has analyzed more than 2.5 million genomic profiles. The platform is designed to be accurate, rapid, and scalable, adhering to strict regulatory standards including HIPAA and GDPR. The company's diverse team from 28 countries includes significant scientific expertise, with 30% holding PhDs. SOPHiA GENETICS operates on a philosophy of 'data for good,' connecting institutions globally while ensuring customers retain full control of their data. The platform offers specialized solutions including SOPHiA DDM™ for Genomics, Radiomics, and Multimodal analysis, along with add-on modules like Alamut Visual Plus and OncoPortal Plus.
Company description Cancer Genetics official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Cancer Genetics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Blood cancers
- Chronic Lymphoblastic Leukemia
- Hereditary cancers
- Inherited disorders
- Kidney cancer
- Liquid biopsy applications
- Myeloproliferative conditions
- Ovarian cancer
- Rare disorders
- Solid tumors
Who it serves
- Bioinformaticians
- BioPharma companies
- Clinical laboratories
- Geneticists
- Healthcare institutions
- Hospitals
- Lab technicians
- Oncologists
- Pathologists
- Radiologists
Deployment & integration
Deployment information is currently being developed.
Geographic context
MarketsGlobal presence across 75+ countries
Company sourceOfficial website
Company milestones
Platform expansion
Partnership with Jessa Ziekenhuis announced at European Congress of Pathology. Laboratorio Barnafi-Krause went live on SOPHiA DDM™. Published collaboration results with UroCCR. Reached 2 million genomic profiles analyzed milestone. Launched SOPHiA DDM™ Enhanced Exome Solutions. Presented at ASCO 2024 and BiotechX USA 2025.
Partnerships
Recorded partners
- French Kidney Cancer Research Network (UroCCR)
- Jessa Ziekenhuis
- Laboratorio Barnafi-Krause
- Memorial Sloan Kettering (MSK-ACCESS®)
- The Royal Marsden NHS Foundation Trust
- TomaLab Advanced Biomedical Assays
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
BRCA1-mutant thymoma and the role of PARP inhibitors: a case report.Pathology · Oct 1, 2026
Unacknowledged Burdens and Clinical Assets of BIPOC Genetic Counseling Students: Qualitative Evidence to Inform Supervision.Journal of genetic counseling · Oct 1, 2026
Understanding Barriers and Motivators of Familial Hypercholesterolemia Genetic Testing: Insights From the Singapore Public.Journal of genetic counseling · Oct 1, 2026
Recent Incidence Trends for Cutaneous T-Cell Lymphoma in the United States: A Surveillance, Epidemiology, and End Results (SEER) Database Analysis, 2000-2022.Journal of the American Academy of Dermatology · Sep 2, 2026
Oxygen-dependent subcellular redistribution of PHD3 links the hypoxic microenvironment to mitochondrial metabolic reprogramming in ccRCC.Experimental & molecular medicine · Sep 2, 2026
Diffusion MRI radiomics in meningiomas: imaging correlates of tumor grade and intraoperative consistency.Neurosurgical focus · Sep 1, 2026
Clinical validation
Clinical-trial records
Genetic Counseling Patient Preference Intervention Versus Conventional Genetic Counseling for Women at Elevated Risk for Breast CancerNCT05325151 · Mentioned · ACTIVE NOT RECRUITING
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With CancerNCT07091617 · Mentioned · RECRUITING
Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) ProjectNCT03326713 · Mentioned · COMPLETED
Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman DiseaseNCT05028621 · Mentioned · SUSPENDED
Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic TestingNCT07387263 · Mentioned · RECRUITING
Chatbot to Maximize Hereditary Cancer Genetic Risk AssessmentNCT05562778 · Mentioned · RECRUITING
Regulatory
Regulatory records
Tissue of Origin Test Kit-FFPEK173839 · 510k · Mar 15, 2018
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
98-99% accuracy
AI algorithm accuracy across multiple health data applications
2.5M+ genomic profiles analyzed
Total genomic profiles processed through platform
Shortened turnaround time
End-to-end workflows for oncology and inherited disorders
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Cancer Genetics
Recent articles published on Cancer Genetics's official website.
How the Future of Genomic Analysis is Already Furthering Breast Cancer Research
Read on Cancer GeneticsIn the Face of Rare Disease: The Inspiring Story of Brooklynn
Read on Cancer GeneticsInternational Childhood Cancer Day 2023: Better survival is achievable!
Read on Cancer GeneticsThe Launch of SOPHiA DDM™ Dispatch
Read on Cancer GeneticsCelebrating Clinical Trials Day
Read on Cancer Genetics07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.